Brief: Reviva Pharmaceuticals Holdings Inc Says Topline Data From Phase 3 Recover Trial For Brilaroxazine Inschizophrenia Expected Mid-2023
01/05/2023 22:41
May 1 (Reuters) - Reviva Pharmaceuticals Holdings, Inc.
RVPH.O :
* REVIVA PHARMACEUTICALS HOLDINGS, INC. - TOPLINE DATA FROM
PHASE
3 RECOVER TRIAL FOR BRILAROXAZINE INSCHIZOPHRENIA EXPECTED
MID-2023
Source text for Eikon: ID:nGNX3zG374
Further company coverage: RVPH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Reviva Pharmaceuticals Holdings
See all newsReviva Pharmaceuticals Q1 net loss narrows on lower expenses
Brief: Reviva Pharmaceuticals Holdings Inc - To Be Delisted From Nasdaq Trading Suspended As Of May 14, 2026 - SEC Filing
Brief: Reviva Reports Full Year 2025 Financial Results And Recent Business Highlights
Reviva Pharmaceuticals' 2025 net loss narrows on lower R&D spending
U.S. STOCKS ON THE MOVE-Darden Restaurants, Mastercard, Accenture